Figure 3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium

6-3-A6 treatment alone or in combination with other chemotherapeutic agents delays tumor growth in human tumor xenografts. A, IF staining of Notch4 (red) and CD31⁺ tumor vessels (green) in additional human tumor xenografts. B, SEKI melanoma human xenografts treated with 6-3-A6 alone, i.v. bevacizumab alone, or lenvatinib alone (n = 5). C, DU145 prostate xenografts treated with i.v. 6-3-A6, i.v. paclitaxel, or combination (n = 4 mice/group). All treatments started 12 hours after tumor implantation. Statistical analysis performed with two-way ANOVA for tumor growth curves, plotted as average ± SEM; *, P < 0.05; **, P < 0.005; ***, P < 0.001.